BACKGROUND: A @entity2774 / @entity5538 ( @entity9063 ) substitution occurring in position -174 of the @entity650 ( @entity650 ) gene promoter changes the expression of @entity650 circulating proteins. We evaluated the occurrence of @entity650 @entity8996 polymorphism in @entity1 with acute @entity385 and studied its association with @entity64 severity, outcome, and mortality. METHODS: One hundred @entity1 with acute @entity385 and 120 age and sex-matched healthy controls were studied. Genotyping was performed using polymerase chain reaction and restriction enzyme analysis. Serum levels of @entity650 were measured using enzyme-linked immunosorbent assay. @entity64 was classified using Trial of @entity10269 in Acute @entity64 Treatment (TOAST) classification. Severity was assessed by the National Institutes of Health @entity64 Scale. Outcome measures included modified Rankin Scale (mRS) and Barthel Index (BI) scores at 7 days and 3 and 6 months. Mortality/survival was assessed using the Kaplan-Meier analysis. RESULTS: The frequency of GG, GC, and CC genotypes did not differ significantly between cases and controls. No association was seen between TOAST subtype and genotype. At the time of admission, @entity64 was more severe in @entity1 with the GC genotype (P = .03) and less severe in the GG genotype (P = .04). The GC genotype was also associated with higher serum @entity650 levels and poor short-term (BI P = .001; mRS P = .003) and long-term outcomes (BI P = 9   10(-5); mRS P = 9   10(-5)), while the GG genotype had significantly lower serum @entity650 levels and better short and long-term outcomes (BI P = 3   10(-5); mRS P = 2   10(-4)). There was significantly lesser mortality in the GG genotype and more in the GC genotype based on the Kaplan-Meier analysis. CONCLUSIONS: @entity1 with the GC genotype had more severe @entity64 with poorer short and long-term outcomes and increased mortality. The GG genotype was associated with less severe @entity64 , better short and long-term prognosis, and survival. The GG genotype appears to be protective against @entity64 severity, outcome, and mortality.

@entity650 gene @entity8996 promoter polymorphism predicts severity and outcome in acute @entity385 XXXX from north India.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity9063 :: ('c|SUB|G||C', 'DNAMutation') :: ['G/C'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke', 'Stroke'] @entity8996 :: ('c|SUB|G|-174|C', 'DNAMutation') :: ['-174 G/C'] @entity2774 :: ('MESH:D006147', 'Chemical') :: ['guanine'] @entity5538 :: ('MESH:D003596', 'Chemical') :: ['cytosine'] @entity10269 :: ('MESH:C035838', 'Chemical') :: ['Org 10172'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1 :: (9606,Species) :: ['patients']
